Summit Therapeutics (SMMT): Ivonescimab Beats Pembrolizumab Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC

Visit StreetInsider.com at http://www.streetinsider.com/Trading+Halts/Summit+Therapeutics+%28SMMT%29%3A+Ivonescimab+Beats+Pembrolizumab+Head-to-Head%2C+Achieves+Statistically+Significant+Superiority+in+PFS+in+First-Line+Treatment+of+Patients+with+PD-L1+Positive+NSCLC/23299911.html for the full story.